Ototoxicity

Dietary Supplements with vegetables in the background

ONLINE FEATURE | Dietary Supplements Used for COVID-19 Treatment

There are no dietary supplements that will cure or prevent disease. With the 2019 coronavirus COVID-19 pandemic, it’s especially important to understand that no supplement, diet, or other lifestyle modification other than physical distancing, also known as social distancing, and proper hygiene practices can protect you from COVID-19.

There is no research to support the use of any dietary supplement to protect against COVID-19. No supplement may claim to diagnose, prevent, treat or cure COVID-19. Consumers and retailers should avoid products that suggest they do.^{1, 2}

Topic(s): COVID-19, Ototoxicity, Patient care, diet, dietary supplements

Author(s):

Robert M. DiSogra

Publication Issue: Audiology Today May/June 2020

Ototoxicity of FDA-Approved Drugs Being Re-Purposed for COVID-19 Treatment

According to the National Institutes of Health’s Center National Center for Advancing Translational Sciences, many drugs approved for other uses already have been tested in humans, so detailed information is available on their pharmacology, formulation, and potential toxicity.

ONLINE FEATURE | Ototoxicity of FDA-Approved Drugs Being Re-Purposed for COVID-19 Treatment

Topic(s): COVID-19, Ototoxicity, FDA, Patient care, Practice Management

Author(s):

Robert M. DiSogra

Publication Issue: Audiology Today May/June 2020

COVID-19 Survivors Treated with Hydroxychloroquine and Azithromycin

By Robert M. DiSogra

Audiologists have known about the ototoxicity of quinine (and its derivatives) and antibiotics (macrolide and aminoglycoside) for decades. But we have never seen the combined use of two drugs, each with known ototoxic potential, being used as an intervention strategy for the coronavirus pandemic (COVID-19).

Coronavirus and combative medication image

ONLINE FEATURE | Audiological Management of COVID-19 Survivors Treated with Hydroxychloroquine and Azithromycin

In an effort to combat the coronavirus (COVID-19), front-line physicians are re-purposing two drugs: hydroxychloroquine (commonly used for malaria and rheumatoid arthritis) and azithromycin (a macrolide antibiotic used to treat common infections of the respiratory system, the ear and the eye). Both drugs are known ototoxic agents; however, there is no published research about the synergistic ototoxic effects of these drugs in treating COVID-19.

Topic(s): COVID-19, Ototoxicity, Hydroxychloroquine, Azithromycin

Author(s):

Robert M. DiSogra

Publication Issue: Audiology Today May/June 2020

COVID-19: Considerations for Treatments Using Quinine Derivatives and Other Ototoxic Compounds

Hydroxychloroquine was recently approved by the U.S. Food and Drug Administration (FDA) for emergency use to treat adults and adolescents with COVID-19.

Ototoxicity and Quality of Life for Cancer Survivors

WHen it comes to the long-term effects of Ototoxicity there are significant shortcomings in the literature and the lack of standardization in report of quality of life. As survival rates increase, emphasis on long-term toxicities, such as hearing loss and tinnitus, will become more and more critical to address.